Researchers at Saint Louis University report via Science Daily the discovery of a targeted gene, the activation of which suppresses pain of neurological maladies and cancer. The meds which target this site do not, it appears, become addictive or hallucinogenic and do not habituate.
So far it has been shown effective only on animal subjects, so development will take several years. A drug which activates the adenosine A3 receptor possibly could be of major help to sufferers of trigeminal neuralgia and fibromyalgia, among other conditions.
